Abstract:Ferroptosis is a recently recognized form of regulated cell death. It is characterized morphologically by the presence of smaller than normal mitochondria with condensed mitochondrial membrane densities, reduction or vanishing of mitochondria crista, and outer mitochondrial membrane rupture. It can be induced by experimental compounds (e.g., erastin, Ras-selective lethal small molecule 3, and buthionine sulfoximine) or clinical drugs (e.g., sulfasalazine, sorafenib, and artesunate) in cancer cells and certain normal cells (e.g., kidney tubule cells, neurons, fibroblasts, and T cells). Activation of mitochondrial voltage-dependent anion channels and mitogen-activated protein kinases, upregulation of endoplasmic reticulum stress, and inhibition of cystine/glutamate antiporter is involved in the induction of ferroptosis. This process is characterized by the accumulation of lipid peroxidation products and lethal reactive oxygen species (ROS) derived from iron metabolism and can be pharmacologically inhibited by iron chelators (e.g., deferoxamine and desferrioxamine mesylate) and lipid peroxidation inhibitors (e.g., ferrostatin, liproxstatin, and zileuton). Glutathione peroxidase 4, heat shock protein beta-1, and nuclear factor erythroid 2-related factor 2 function as negative regulators of ferroptosis by limiting ROS production and reducing cellular iron uptake, respectively. In contrast, NADPH oxidase and p53 (especially acetylation-defective mutant p53) act as positive regulators of ferroptosis by promotion of ROS production and inhibition of expression of SLC7A11 (a specific light-chain subunit of the cystine/glutamate antiporter), respectively. Misregulated ferroptosis has been implicated in multiple physiological and pathological processes, including cancer cell death, neurotoxicity, neurodegenerative diseases, acute renal failure, drug-induced hepatotoxicity, hepatic and heart ischemia/reperfusion injury, and T-cell immunity. In this review, we summarize the regulation mechanisms and signaling pathways of ferroptosis and discuss the role of ferroptosis in disease.

Ferroptosis Regulation by Nutrient Signalling

Targeting Ferroptosis in Breast Cancer

The role of non-coding RNAs in ferroptosis regulation

Targeting Ferroptosis for Cancer Therapy: Exploring Novel Strategies from Its Mechanisms and Role in Cancers

Nutritional and Metabolic Control of Ferroptosis

Ferroptosis: principles and significance in health and disease

Important molecular mechanisms in ferroptosis

Ferroptosis: From regulation of lipid peroxidation to the treatment of diseases

Understanding the unique mechanism of ferroptosis: a promising therapeutic target

Ferroptosis: process and function

Ferroptosis: Iron-mediated cell death linked to disease pathogenesis

Ferroptosis Regulated by Hypoxia in Cells

Dynamic regulation of ferroptosis by lipid metabolism.

The Molecular Mechanisms of Regulating Oxidative Stress-Induced Ferroptosis and Therapeutic Strategy in Tumors

Ferroptosis: molecular mechanisms and health implications

Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease

Energy metabolism as a regulator of ferroptosis

Focus on ferroptosis regulation: Exploring novel mechanisms and applications of ferroptosis regulator

The Application of Ferroptosis in Diseases

The mechanism of ferroptosis and its related diseases

The emerging roles of MAPK-AMPK in ferroptosis regulatory network